Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.68 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.57 |
| ▸ | OPRD1 known ✓ | P41143 | 3/20 | 0.57 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15734501 | 0.84 | DRD3 (0.70) | DRD3OPRM1OPRD1OPRK1LMNA | |
| Hydrochloric Acid SCHEMBL3321232 | 0.81 | OPRM1 (0.70) | DRD3OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL19475378 | 0.81 | DRD3 (0.68) | DRD3OPRM1OPRD1OPRK1LMNA | |
| Hydrochloric Acid SCHEMBL29427663 | 0.81 | DRD3 (0.54) | DRD3OPRM1OPRD1OPRK1MEN1 | |
| Hydrochloric Acid SCHEMBL29375521 | 0.81 | DRD3 (0.54) | DRD3OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL11458105 | 0.80 | DRD3 (0.67) | DRD3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL614226 | 0.79 | OPRM1 (0.71) | DRD3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL19717856 | 0.77 | DRD3 (0.64) | DRD3OPRM1OPRD1OPRK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30932709 | 0.76 | DRD3 (0.60) | DRD3OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL28398971 | 0.76 | OPRM1 (0.65) | DRD3OPRM1OPRD1OPRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615579-A1 | ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2 | Generate Biomedicines, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4519310-A1 | ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2 | Generate Biomedicines, Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| WO-2024102674-A9 | ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2 | GENERATE BIOMEDICINES, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-20240360203-A1 | Antigen Binding Molecules Targeting SARS-CoV-2 | GENERATE BIOMEDICINES, INC. | 2024-10-31 | — | — | US | claimed |
| WO-2024050421-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-03-07 | — | — | WO | claimed |
| US-20230357366-A1 | Antigen Binding Molecules Targeting SARS-CoV-2 | GENERATE BIOMEDICINES, INC. | 2023-11-09 | — | — | US | claimed |
| US-20230357367-A1 | Antigen Binding Molecules Targeting SARS-CoV-2 | GENERATE BIOMEDICINES, INC. | 2023-11-09 | — | — | US | claimed |
| WO-2023215910-A1 | ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2 | GENERATE BIOMEDICINES, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| CN-122055379-A | Compounds containing one or more diboronate esters and related insulin analogues | 普罗托莫科技公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4615579-A1 | ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2 | Generate Biomedicines, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250197416-A1 | PARTHENOLIDE DERIVATIVES AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230357367-A1 | Antigen Binding Molecules Targeting SARS-CoV-2 | GENERATE BIOMEDICINES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11795146-B2 | Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof | ANEBULO PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230139815-A1 | CRYSTALLINE FORMS OF A CANNABINOID RECEPTOR TYPE 1 (CB1) MODULATOR AND METHODS OF USE AND PREPARATION THEREOF | ANEBULO PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-116004597-A | Carbohydrate metabolism related protein IbpBM, biological material and application thereof | 河南省农业科学院粮食作物研究所 | 2023-04-25 | — | — | CN | disclosed |
| US-20220206001-A1 | METHODS AND SYSTEMS FOR DETECTING CORONAVIRUS | TWIST BIOSCIENCE CORP (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795146-B2 | Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof | CNR1, CNR2, GPR18 | DRD3 1437/4885OPRM1 6/4885OPRD1 39/4885 |
| US-20250197416-A1 | PARTHENOLIDE DERIVATIVES AND USE THEREOF | CASP8, WEE1, CASP7 | DRD3 2278/4885OPRM1 1615/4885OPRD1 2848/4885 |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, ACHE, AADAC | DRD3 2832/4885OPRM1 3050/4885OPRD1 2065/4885 |
| US-20230139815-A1 | CRYSTALLINE FORMS OF A CANNABINOID RECEPTOR TYPE 1 (CB1) MODULATOR AND METHODS OF USE AND PREPARATION THEREOF | CNR1, CNR2, GPR18 | DRD3 1437/4885OPRM1 6/4885OPRD1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.